Genetic prodrug activation therapy

A Rigg1, K Sikora

  • 1ICRF Molecular Oncology Unit, Imperial College of Medicine, Hammersmith Hospital, London, UK. a.rigg@icrf.icnet.uk

Insights

Genetic prodrug activation therapy uses gene therapy to convert inactive drugs into cancer-killing agents specifically in targeted cells. Developing safe gene delivery systems remains a key challenge for this promising treatment.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Genetic prodrug activation therapy offers a novel approach for treating various diseases, including cancer.
  • This therapy involves introducing a gene for a drug-metabolizing enzyme into cells.
  • The enzyme then converts a systemically administered prodrug into a cytotoxic agent.

Purpose of the Study:

  • To explore the potential of genetic prodrug activation therapy.
  • To highlight the mechanism of targeted enzyme expression for localized drug activation.
  • To identify challenges in gene delivery for clinical application.

Main Methods:

  • Utilizing transcriptional regulation of a gene unique to target cells to control enzyme expression.
  • Employing gene therapy principles for localized prodrug conversion.
  • Systemic administration of a prodrug for activation within targeted cells.

Main Results:

  • Demonstrated the principle of targeted enzyme expression for specific prodrug activation.
  • Showcased the potential for localized cytotoxic agent generation.
  • Identified gene delivery systems as a critical hurdle for clinical translation.

Conclusions:

  • Genetic prodrug activation therapy is a promising strategy for cancer and other diseases.
  • Precise control over enzyme expression in target cells is achievable.
  • Advancements in safe and effective gene delivery are crucial for clinical success.

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...